Supportive Care in Oncology-Significant growth opportunities in new supportive care indications

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-06-15

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Supportive care can be defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies, in particular cytotoxic chemotherapy. While the antihormonal therapies and novel molecular targeted therapies do not exist without some toxicity, these are not as severe as those associated with chemotherapy.


Scope

  • Overview of the current oncology supportive care market, including profiles of key marketed products and events impacting each during 200616
  • Examination of the oncology supportive care pipeline with in-depth clinical and commercial profiles of Phase III and some key Phase II candidates
  • Seven-market sales forecasts from 2006 to 2016 for branded oncology supportive care products and key pipeline candidates
  • Detailed discussion of key strategic issues in the oncology supportive care market, including one commercial impact case study


    • Report Highlights
    The oncology supportive care market is forecast to undergo slightly positive growth at a CAGR of 0.6%, from a seven-market sales total of $13,763m in 2006 to $14,679m in 2016. This low level of growth is largely due to an increasing level of patent expiry and generic competition, including the impending launch of biosimilars in the EU.

    The erythropoietins class has come under increasing levels of scrutiny of late due to emerging doubts over safety of these products. As a result the FDA and EMEA are recommending more restrictive conditions for use and increased monitoring of patients. It is expected that sales of these products will suffer as a result of these restrictions.

    Any significant future growth in the oncology supportive care market will likely come from product development in new indications, such as EGFR-inhibitor associated skin rash. However, given the early-phase of clinical development for such products, it will be some time before any impact is made and true future potential can be determined.


    Reasons to Purchase

  • Understand market specific drivers and predict the future potential of key marketed and pipeline oncology supportive care products
  • Assess the impact of product launches and identify the opportunities and risks for key products within the oncology supportive care market
  • Adopt knowledge to drive strategic planning for marketed products and optimize the market penetration of new entrants

    • Table of Contents

    Other users found this report page using the following search terms: supportive care cancer oncology antinauseants nausea vomiting antiemetics pain infection control neutropenia anemia ppt oncology care supportive sancuso patent market expiry aloxi growth

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.